Oral antiplatelet therapy in unstable angina/non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and percutaneous coronary intervention: is it time for a guideline update? Am J Cardiol 2009 Sep 07;104(5 Suppl):4C-8C
Date
08/27/2009Pubmed ID
19695354DOI
10.1016/j.amjcard.2009.06.019Scopus ID
2-s2.0-68749101001 (requires institutional sign-in at Scopus site) 1 CitationAbstract
Oral antiplatelet drugs are central in the management of acute coronary syndromes, including unstable angina/non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and percutaneous coronary intervention. However, the mechanisms that confer the benefits of these agents also increase bleeding risk. Thus, the selection of appropriate pharmacotherapy requires close attention to the delicate balance between reducing the risk of ischemic events and minimizing bleeding risk. A critical review of the 2007 guidelines in these areas and new clinical data with currently available and soon-to-be-approved antiplatelet agents are presented.
Author List
Saucedo JFAuthor
Jorge Saucedo MD Chief, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Acute Coronary SyndromeAdministration, Oral
Angioplasty, Balloon, Coronary
Humans
Myocardial Infarction
Platelet Aggregation Inhibitors
Practice Guidelines as Topic